DC
AXDX

Destiny Capital’s Accelerate Diagnostics AXDX Stock Holding History

Destiny Capital’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$31K Hold
3,831
– – 0.02% 52
2023
Q1 		$26.8K Hold
3,831
– – 0.02% 48
2022
Q4 		$25.3K Buy
+3,831
New +$41.8K 0.02% 44

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Destiny Capital's AXDX Position: Q2 2023 in Review

Destiny Capital held its Accelerate Diagnostics (AXDX) position steady in Q2 2023 at 3,831 shares worth $31K. The position accounts for 0.02% of the portfolio, ranked #52.

Destiny Capital first reported a position in AXDX in Q4 2022 and has held it in 3 quarters since. 51 funds tracked by Wall St. Rank hold AXDX as of Q2 2023.

  • Destiny Capital held 3,831 shares of Accelerate Diagnostics worth $31K as of Q2 2023.
  • Destiny Capital left its Accelerate Diagnostics share count unchanged in Q2 2023.
  • Accelerate Diagnostics made up 0.02% of Destiny Capital's portfolio in Q2 2023, its #52 holding.
  • Destiny Capital first reported a position in Accelerate Diagnostics in Q4 2022 and has held it in 3 quarters since.
  • 51 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2023.

Based on Destiny Capital's 13F filing for Q2 2023, filed 3 Aug 2023.